- Home
- LYRA vs BCLI Comparison
LYRA vs BCLI Comparison
Compare LYRA & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BCLI
- Stock Information
- Founded
- LYRA 2005
- BCLI 2000
- Country
- LYRA United States
- BCLI United States
- Employees
- LYRA N/A
- BCLI N/A
- Industry
- LYRA Medical/Dental Instruments
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYRA Health Care
- BCLI Health Care
- Exchange
- LYRA Nasdaq
- BCLI Nasdaq
- Market Cap
- LYRA 11.8M
- BCLI 9.9M
- IPO Year
- LYRA 2020
- BCLI N/A
- Fundamental
- Price
- LYRA $0.12
- BCLI $1.19
- Analyst Decision
- LYRA Hold
- BCLI Strong Buy
- Analyst Count
- LYRA 4
- BCLI 1
- Target Price
- LYRA $1.25
- BCLI $30.00
- AVG Volume (30 Days)
- LYRA 828.8K
- BCLI 34.1K
- Earning Date
- LYRA 03-13-2025
- BCLI 03-31-2025
- Dividend Yield
- LYRA N/A
- BCLI N/A
- EPS Growth
- LYRA N/A
- BCLI N/A
- EPS
- LYRA N/A
- BCLI N/A
- Revenue
- LYRA $1,534,000.00
- BCLI N/A
- Revenue This Year
- LYRA N/A
- BCLI $170.09
- Revenue Next Year
- LYRA $519.89
- BCLI N/A
- P/E Ratio
- LYRA N/A
- BCLI N/A
- Revenue Growth
- LYRA N/A
- BCLI N/A
- 52 Week Low
- LYRA $0.12
- BCLI $1.05
- 52 Week High
- LYRA $6.29
- BCLI $11.25
- Technical
- Relative Strength Index (RSI)
- LYRA 23.27
- BCLI 28.41
- Support Level
- LYRA $0.14
- BCLI $1.12
- Resistance Level
- LYRA $0.20
- BCLI $1.59
- Average True Range (ATR)
- LYRA 0.01
- BCLI 0.11
- MACD
- LYRA -0.00
- BCLI -0.02
- Stochastic Oscillator
- LYRA 1.05
- BCLI 10.53
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.